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A B S T R A C T Patients lacking high molecular weight (HMW) kininogen have profound abnormalities of the Hageman factor-dependent pathways of coagulation, kinin formation, and fibrinolysis. The ability of HMW kininogen to potentiate the Hageman factor fragments (HFf activation of prekallikrein and Factor XI in plasma was studied. HFf only partially converted Factor XI to XIa and prekallikrein to kallikrein in plasma deficient in HMW kininogen (Williams trait), while enhanced activation of Factor XI and prekallikrein by HFf resulted after reconstitution with HMW kininogen. In a system using highly purified components, HMW kininogen increased the initial rate of prekallikrein activation whether the kallikrein formed was assayed by arginine esterase activity or kininforming ability. The potentiation of prekallikrein activation occurred over a 12-fold range of enzyme (HFf) concentration and was nonhyperbolic with respect to substrate (prekallikrein). HMW kininogen exerted its effect even in the absence of prekallikrein since the hydrolysis of acetylglycyl-lysine methyl ester by HFf was increased by HMW kininogen. These results suggest that one of the functions of HMW kininogen is to augment the catalytic action of HFf.
INTRODUCTION
The adsorption and activation of Factor XII (Hageman factor [HF]1 on a negatively charged surface is known to initiate the coagulation (1), fibrinolytic (2) , and kinin-forming pathways (3) . Initially, it was suggested that only activated Hageman factor (HFa) was necessary for the subsequent activation of each of these pathways and it was assumed that activation of HF occurred upon binding to certain negatively charged surfaces. Subsequently, the abnormal rate of activation of these three plasma proteolytic pathways in Fletcher trait plasma (4) was attributed to a deficiency of prekallikrein (5) . This absence ofprekallikrein was shown to result in a diminsihed rate of formation of HFa (6) . However, other observations (7) (8) (9) suggested that yet another factor was required for normal activation and function ofthe HF-dependent pathways.
The unravelling of this conundrum was made possible by the investigation of several unusual but asymptomatic patients (Williams, Fitzgerald, Flaujeac) whose plasma samples exhibited profound abnormalities of all the Hageman-dependent pathways (10) (11) (12) . Assays for the known coagulation factors were normal except for prekallikrein which while diminished in four cases (10, 11, 13, 14) was insufficient to account for the observed abnormalities. Since then, two other patients (13, 14) have been described with similar abnormalities ofthe Hageman-dependent pathways. Three ofthe patients (10, 12, 13) had absent or very low levels of both high and low molecular weight kininogens whereas Fitzgerald (11) had 50% low molecular weight kininogen. A high molecular weight (HMW) subfraction of kininogen was able to correct the abnormalities in each of these patients' plasma. HMW kininogen therefore appeared to be a critical factor required for the functioning of HF-dependent coagulation, and fibrinolysis and for the activation of prekallikrein.
HMW kininogen could accelerate Hageman factor catalyzed reactions by three mechanisms. It might facilitate the transformation of unactivated HF to HFw enhance the conversion of HF or HFa to its fragments (HFf) and/or potentiate the action of activated HF upon its substrates. This report deals with the third possibility by examining the effect of HMW kininogen upon the ability of HFf to activate prekallikrein and Factor XI and cleave the synthetic substrate acetylglycyl-lysine methyl ester. HF-deficient and Factor XI-deficient plasma were prepared from the blood of severely deficient patients collected by George King Bio-Medical, Inc., Salem, N. H., in 0.1 vol 3.8% citrate, centrifuged at 5,000 g for 20 min, fresh-frozen and stored in 1-ml aliquots at -70°C. Prekallikrein-deficient plasma was a gift from Dr. C. Abildgaard (University of California, Davis, Calif.). The blood was drawn and handled as described below for normal donors. Anti-human plasma kallikrein antibody was prepared in rabbits and adsorbed with prekallikrein-deficient plasma as described previously (15) . Sheep antibody to human low molecular weight kininogen was prepared as previously reported (16, 17) .
METHODS
Preparation of plasma proteins. To obtain normal human plasma for use in assays, nine volumes of blood from healthy donors was drawn directly into plastic syringes containing one volume of 3.8% citrate. The blood was transferred to plastic tubes and centrifuged at 5,000 g at 4°C for 15 min to remove the cells. Plasma was removed and a pool was made from 20 normal male donors. 1-ml aliquots of the pool were stored at -70°C and used immediately after thawing. Any residual plasma was discarded. Plasma from Ms. Williams was collected and handled identically.
Plasma utilized for the isolation of prekallikrein, and kininogen was collected in plastic syringes with the same citrate anticoagulant as described previously. For each 10 ml of blood drawn, 3.6 mg of hexadimethrine bromide in 0.1 ml of 0.15 M NaCl was added. The blood was centrifuged at 900 g for 20 min at 4°C and the plasma was removed with plastic pipettes. Plastic columns and test tubes were utilized throughout all chromatographic procedures to minimize contact activation of HF. Samples were concentrated by ultrafiltration through a PM-10 membrane (Amicon Corp., Scientific Sys. Div., Lexington, Mass.). Gel filtration Sephadex G-150, alkaline disc gel electrophoresis, and sodium dodecyl sulfate gel electrophoresis were performed as described previously (18 by the method of Pierce, Guimaraes, and Chenlu2 described briefly in early reports (10, 23, 24) . Human plasma diluted 1:5 with distilled water containing 0.1 mg/ml hexadimethrine bromide was stirred with DE-23 cellulose at pH 6.0, 250C. Elution was performed with 0.4 M Tris-HCl, pH 6.0. The eluate, adjusted to pH 7.1, was absorbed onto an anti-low molecular weight kininogen insolubilized by coupling to Sepharose 4B with cyanogen bromide. The kinonogen was eluted with 8 M guanidine, dialyzed, and chromatographed on DEAE-cellulose at 4°C. Four main peaks of kininogen activity Bi, B2, B3, and B4
were eluted by a gradient of 0.05-0.30 M sodium phosphate, pH 6.0. Gel filtration of the B4 peak on Bio-Gel A 0.5 m at 250C yielded kininogens with apparent mol wt of 80,000, 160,000, and 225, 000 called B4a, B4,3, and B4y, respectively (24) which corrected the abnormalities in Williams trait plasma (10) . The preparations ob B4y and B4f3 kininogen utilized in these experiments were both 0.1 mg/ml protein and contained 1.0 U/ml HMW kininogen as assayed by a functional clotting assay (see below). These two kininogens were used interchangeably and gave similar results and are 2 Manuscript in preparation. designated HMW kininogen. B4y kininogen yielded a single major band on alkaline disc gel electrophoresis (10) . This HMW kininogen preparation at a concentration of 1.0 U/ml demonstrated <0.01 U/ml of Factor XI or prekallikrein, <0.3% of the Cl esterase inhibitor in normal plasma and zero kallikrein esterase units. No immunoprecipitates were demonstrable by radial immunodiffusion against antisera to Cl esterase inhibitor, a2-macroglobulin, a1-antitrypsin, alantichymotrypsin, and inter a1-antitrypsin. In addition, HMW kininogen failed to inhibit kallikrein in an amidolytic assay and plasmin in a fibrin plate assay. The low molecular weight kininogens B2a and B3-2a described previously ( (25) , which has been described in detail (26) . Since HFf was used as the activator of prekallikrein, kaolin was ommited. One unit of kallikrein esterase activity is the amount of kallikrein which will hydrolyze 1 ,umol of TAMe/min at 37°C. The proteolytic activity of kallikrein was measured by its ability to release bradykinin, a substrate consisting of heat-inactivated plasma, containing 3 mM o-phenanthroline (27) . Bradykinin was quantitated by bioassay (27) Prekallikrein was determined by incubation of ,ul of proenzyme source with 25 ul of HFf (6 ,ug/ml) for 18 min at 370C and kallikrein was assayed by either arginine esterase activity or kinin-forming activity as indicated in Results. The immunoassay for prekallikrein was performed by the method of Bagdasarian et al. (15) .
Kininogens were assayed functionally by two methods as previously described (10, 24) .
Assay of HMW kininogen, Factor XI, and prekallikrein coagulant activity. A standard curve was constructed by serially diluting normal plasma (1:10, 1:20, 1:50, and 1:100). 100 .ul of the diluted plasma was mixed on ice with 100 ,ul of the undiluted deficient plasma in a glass tube. 100 IAl of 5 mg/ml kaolin in 0.15 M NaCl, and 100 gl of 0.2% inosithin in 0.02 M Na barbital, pH 7.4, containing 0.15 M NaCl were added. The mixture was incubated at 370C for 5 min except in the prekallikrein assay which was incubated for 2 min. The mixture was then recalcified with 100 ,ul of0.03 M CaCl2 in 0.15 M NaCl (28) . A standard curve relating log clotting time to log dilution was plotted. A linear relationship was observed. Experimental samples were assayedby diluting 10 ,ul of the sample with 90 ,ul of the barbital buffer and perforrning the partial thromboplastin time in the same manner as the standard curve. The clotting time of the sample was then related to percent of normal pooled plasma by interpolation on the standard curve. One unit of Factor XI, prekallikrein, or HMW kininogen was defined as the amount present in 1 ml of normal plasma (pool of 20 normal individuals). Factor XIa was assayed performing a partial thromboplastin time using Factor XI-deficient plasma in the absence of kaolin and in plastic tubes.
Assay of HFf using AGLMe hydrolysis. 20 ,ul of HFf (60 ,ug/ml) was incubated with 90 ,ll of various concentrations of AGLMe containing 2 mg/ml of bovine serum albumin at 37°C for time periods of 30-90 min, and the activity determined by a modification of the method described by Ulevitch et al. (29) . The enzymatic activity of HFf was linear with enzyme concentration for time periods extending to 90 min.
RESULTS
The effect ofHMW kininogen on Factor XI and prekallikrein activation by HFf in plasma Factor XI activation. Previous studies have demonstrated (10, (12) (13) (14) or suggested that (11) plasma deficient in HMW kininogen also shows defective Factor XI activation by kaolin. To decide whether this coagulation abnormality was also attributable to an inability to potentiate the coagulant activity of HFa, we used HFf as the enzyme to attempt the conversion of Factor XI to Factor XIa in plasma deficient in Factor XII and HMW kininogen (Table I) . Activation of Factor XI in Factor XII-deficient plasma by HFf, was essentially the same as activation of Factor XI in normal plasma. In contrast, Factor XI. formation in HMW kininogen-deficient plasma was diminished to about one-third of normal. This abnormality was fully corrected upon reconstitution ofthe plasma with HMW kininogen to 12% of normal pooled plasma, a level sufficient to correct the coagulation abnormality of HMW kininogen deficiency (10, 12, 13 peared that HMW kininogen increased the rate of HFf conversion of prekallikrein to kallikrein. Generation of kinin-forming activity. HFf was incubated with prekallikrein in the presence or absence of HMW kininogen and the kinin released from heated plasma was determined by bioassay (Fig. 4 ). An increased rate of formation of kallikrein proteolytic activity in the presence of HMW kininogen was observed similar to that seen with ester hydrolysis. HMW kininogen incubated with HFf and prekallikrein generated 0.05 ,ug kinin/ml per 5 min which was 5% of the kinin released from the heated plasma by the same mixture (1. 1 ,ug/ml per 5 min). A mixture of prekallikrein (1.0 kallikrein esterase unit/ml) and HMW kininogen (0.1 U/ml) after incubation for 5 min released 0 gg/ml kinin equivalents. Since the effect of HMW kininogen appeared to be upon the initial rate of prekallikrein activation rather than the yield of kallikrein, the kinetics of activation were followed over the first 60 s of the reaction after decreasing the HFf concentration fivefold (Fig. 5) . The initial rate of the reaction was linear with and without HMW kininogen for the first 30 s. Potentiation occurred at the earliest time measured (10 s) and was similar in magnitude (twofold) to the increase in initial rate observed when esterase activity was measured. Since no major differences in these experiments were evident whether kallikrein was assayed by esterase or kinin-releasing activity, only the esterase activity will be reported in the subsequent experiments.
Effect of HFf concentration on acceleration of prekallikrein activation. Since HMW kininogen might affect the enzyme (HFf) and/or the substrate (prekalli- 0 2 4 6 8 10 12 14 HFf (sg/ml) FIGURE 6 Prekallikrein (0.75 kallikrein esterase units) in 20 ,ul was incubated with various concentrations of HFf for 1 min at 37°C in the presence (U) and absence (0) of HMW kininogen (final concentration 0.1 U/ml in total volume of 100 ,ul). The initial velocity (Vi) of kallikrein formation was determined by the arginine esterase assay after addition of 1 ml of 0.05 M TAMe. The mean and SEM of four replicate experiments are shown. The significance of the differences at krein) in the activation reaction, the initial rate of activation of prekallikrein by HFf was measured as a function ofthe enzyme concentration (Fig. 6) . Potentiation of prekallikrein conversion to kallikrein was observed in the presence of HMW kininogen. The percent enhancement was pronounced at low HFf concentration, but was not significant at 6 and 12 ,ug/ml HFf. However the increase in kallikrein generated was similar for all concentrations of HFf tested. A mixture of HFf (12 ,ug/ml) and prekallikrein (0.75 kallikrein esterase units/ml) hydrolyzed 2.1 ,umol TAMe/ min per ml while a mixture of the same concentration of prekallikrein and HMW kininogen (0.1 U/ml) hydrolyzed 0.003 ,umol TAMe/min per ml.
Effect of prekallikrein concentration on the rate of kallikrein formation. The initial rate of activation of prekallikrein by HFf was next measured as a function of prekallikrein concentration (Fig. 7) . The ability of HMW kininogen to augment the function of HFf was apparent at low concentrations of prekallikrein. Under these conditions, there were no significant differences observed when prekallikrein concentrations were above 0.4 U/ml kallikrein esterase activity. At concen- (units kallikrein esterase activity/ml) FIGURE 7 Prekallikrein (37.5 esterase units/ml) at various concentrations indicated on the abscissa was incubated with HFf (6 Ag/ml) in a total volume of 100 ,ul for 1 min at 370C in the presence (U) and absence of HMW kininogen (0) (0.1 U/ml). The initial velocity (Vi) of kallikrein formation was determined by the arginine esterase activity. The mean and SEM of five determinations are shown.
The significance ofthe differences at prekallikrein concentrations at kallikrein esterase units of 0.08 (P < 0.01), 0.20 (P < 0.001), 0.36 (P < 0.05), 0.56 (P > 0.10), 0.80 (P > 0.10) were determined using Student's t test. The equation of the line determined by linear regression for the rate of the presence of HMW kininogen is y = 0.058x (r = 0.99, P < 0.001). trations of 0.1 and 0.2 U/ml, a twofold potentiation by HMW kininogen was noted which was significant (P < 0.01) by Student's t test. The plot of initial velocity vs. substrate concentration does not describe a hyperbolic curve typical of Michaelis-Menten kinetics in the absence or presence of HMW kininogen. However, the kinetics approached a linear function in the presence of HMW kininogen.
Effect ofHMW kininogen concentration on prekallikrein activation. The potentiation of HFf conversion of prekallikrein to kallikrein is also a function of the concentration of HMW kininogen added. As shown in Fig. 8 , augmentation of the activity of HFf was maximal at 0.06 U/ml, of HMW kininogen (6 ,ug/ml protein) and a further increase in HMW kininogen concentration yielded less potentiation. At the optimal concentration, a threefold augmentation of the initial rate was noted. Low molecular weight kininogens (B2a and B3.2a) (24) and bovine serum albumin all at concentrations ranging from 1 to 40 ,ug/ml final concentration failed to increase prekallikrein conversion to kallikrein above that seen with HFf alone. Thus, the effect is not merely one of preventing loss of kallikrein activity.
Effect of HMW kininogen on the esterase activity of HFf. HMW kininogen might alter the substrate prekallikrein to increase its susceptibility to enzymatic attack or HMW kininogen might alter the enzyme HFf to potentiate its function. In an attempt to distinguish between these two possibilities, the effect of HMW kininogen upon the ability of HFf to hydrolyze the synthetic substrate AGLMe was examined (29 (10) (11) (12) (13) (14) has led to the identification of HMW kininogen (10, 12, 13) as a critical factor required for normal activation and/or function of HF. These patients fail to convert prekallikrein to kallikrein or release kinin upon incubation with kaolin. Although each plasma was subsequently shown to be deficient in HMW kininogen (10) (11) (12) (13) , three had little or no low molecular weight kininogen (10, 12, 13) Tables I  and II , it appears clear that the action of HFf to activate both Factor XI and prekallikrein was significantly augmented by the reconstitution of HMW kininogen-deficient plasma with HMW kininogen. It has been demonstrated that HFf is a much less potent Factor XI activator than surface-activated Factor XII (19, 27, 30, 31) . Thus in these experiments much higher concentrations of HFf are needed for Factor XI activation (Table I ) than for prekallikrein activation (Table II) .
It appeared possible that the HMW kininogen enhanced the activity of the enzyme, HFf, and/or altered the protein substrates prekallikrein and Factor XI to facilitate this interaction. The prekallikrein-activating pathway was then studied using highly purified components. Activation ofprekallikrein occurred in the absence of HMW kininogen whether measured by arginine esterase activity ( Figs. 1 and 2 ) or kinin formation (Figs. 3 and 4) . However, in each case, the presence of HMW kininogen significantly potentiated the formation of kallikrein. This type of behavior is qualitatively analogous to that seen in the conversion of prothrombin to thrombin. Factor Xa cleaves prothrombin to form thrombin in the presence of phospholipid and calcium but the rate is slow (32) . In the presence of a high molecular weight protein, Factor V, the rate is markedly enhanced (33) . A similar situation is seen in the conversion of Factor X to Factor Xa by IXa in which Factor VIII functions as a high molecular weight cofactor (34 Meier et al. (36) , and Griffin and Cochrane (37) . The optimal concentration of HMW kininogen added in the purified system corresponds to the quantity which was required to fully reconstitute HMW kininogen-deficient plasma (10) .
When the rate of prekallikrein activation was assessed as a function of prekallikrein concentration, a nonhyperbolic curve was obtained. (38) and it is therefore possible that HMW kininogen also facilitates the ability of prekallikrein to be cleaved by activated HF. HMW kininogen does not inhibit the activity of kallikrein in the fluid phase; interestingly, Ratnoff and Saito (39) have reported that kaolin inhibits the amidolytic activity of kallikrein and HMW kininogen reverses this inhibition. However, IgG and cytochrome c had the same effect thus, the specificity of this observation is questionable.
Both the apparent Km and Vma, were decreased by HMW kininogen resulting in an increase in the initial rate at low AGLMe concentrations. In the Michaelis-Menten treatment, if E + S kr (ES) -* E + P, k2 then k3 + k2 Km = ki and Vmax = k3 (E total). Since V, decreases proportionately to Km it is possible that only k3 is decreased. An effect on enzyme-substrate complex dissociation was also found when the potentiation of Factor V upon Factor Xa esterase activated was analyzed (40) . In the latter case, Km and Vmax increased so that Factor V promoted Xa arginine esterase activity only at high substrate concentration.
Thus it appears that HMW kininogen acts at multiple steps in the early phases of plasma proteolysis. First, it enhances the function of surface activated HF (36, 37, 41, 42) upon its substrates. This initial enhancement of HFa generates sufficient kallikrein so that the more rapid enzymatic activation of HF by kallikrein can proceed (36, 37, 41) . HMW kininogen also then facilitates this activation of HF by kallikrein (36, 37) . Furthermore, HMW kininogen and prekallikrein circulate together as a complex (38) , are presumably bound to surfaces together, and then interact with surface-bound HF. The present study demonstrates that HMW kininogen potentiates the activity of HFf in the absence of a surface whether HFf is assayed using its protein substrates prekallikrein and Factor XI or a synthetic ester. This finding suggests that HMW kininogen may augment the action of HFa upon its natural substrates by an alteration of a HF catalytic site.
